Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1991 Aug;66(2):134–138. doi: 10.1136/hrt.66.2.134

A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction.

J D Gemmill 1, K J Hogg 1, P D MacIntyre 1, N Booth 1, A P Rae 1, F G Dunn 1, W S Hillis 1
PMCID: PMC1024603  PMID: 1909151

Abstract

OBJECTIVE--To examine the efficacy, safety, and the pharmacokinetic profile of a bolus dose administration regimen of alteplase in the treatment of acute myocardial infarction. DESIGN--An open pilot study. SETTING--District general hospital. PATIENTS--33 suitable consecutive patients presenting within six hours of the onset of symptoms who satisfied the electrocardiographic criteria for acute myocardial infarction. INTERVENTIONS--Two intravenous boluses of 35 mg alteplase, 30 minutes apart. MAIN OUTCOME MEASURES--Angiographic coronary patency at 90 minutes and 24 hours. Plasma alteplase concentration-time profile and pharmacokinetic analysis. RESULTS--Coronary patency at 90 minutes: 26 of 30 arteries (87%, 95% confidence interval (CI) 74-99%). Coronary patency at 24 hours: 24 of 29 arteries (83%, CI 69-97%). Mean (SD) plasma tissue plasminogen activator (t-PA) concentration reached 4434.8 (2117.8) and 4233.3 (2217.5) ng/ml within 10 minutes of each bolus and fell to 425.8 (288.3) ng/ml between boluses. The estimated peak concentrations at two minutes after boluses were 12,389 (8580) ng/ml and 10,811 (6802) ng/ml. The derived pharmacokinetic variables were volume of distribution 3.11 (1.89) 1, clearance 21.3 (9.3) 1/h, half life 5.9 (1.7) minutes. CONCLUSIONS--This simple administration regimen achieved brief, high concentrations of plasma t-PA that were well tolerated. The regimen was associated with a high coronary patency rate at 90 minutes that was well maintained at 24 hours.

Full text

PDF
134

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chesebro J. H., Knatterud G., Roberts R., Borer J., Cohen L. S., Dalen J., Dodge H. T., Francis C. K., Hillis D., Ludbrook P. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987 Jul;76(1):142–154. doi: 10.1161/01.cir.76.1.142. [DOI] [PubMed] [Google Scholar]
  2. Collen D., Topol E. J., Tiefenbrunn A. J., Gold H. K., Weisfeldt M. L., Sobel B. E., Leinbach R. C., Brinker J. A., Ludbrook P. A., Yasuda I. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation. 1984 Dec;70(6):1012–1017. doi: 10.1161/01.cir.70.6.1012. [DOI] [PubMed] [Google Scholar]
  3. DeWood M. A., Spores J., Notske R., Mouser L. T., Burroughs R., Golden M. S., Lang H. T. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980 Oct 16;303(16):897–902. doi: 10.1056/NEJM198010163031601. [DOI] [PubMed] [Google Scholar]
  4. Garabedian H. D., Gold H. K., Leinbach R. C., Johns J. A., Yasuda T., Kanke M., Collen D. Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. J Am Coll Cardiol. 1987 Mar;9(3):599–607. doi: 10.1016/s0735-1097(87)80054-2. [DOI] [PubMed] [Google Scholar]
  5. Hillis W. S., Jones C. R., Been M., Campbell B. C., Fulton W. F. Intracoronary thrombolytic therapy performed within a coronary care unit: one year's experience. Scott Med J. 1986 Jan;31(1):25–29. doi: 10.1177/003693308603100106. [DOI] [PubMed] [Google Scholar]
  6. Khan M. I., Hackett D. R., Andreotti F., Davies G. J., Regan T., Haider A. W., McFadden E., Halson P., Maseri A. Effectiveness of multiple bolus administration of tissue-type plasminogen activator in acute myocardial infarction. Am J Cardiol. 1990 May 1;65(16):1051–1056. doi: 10.1016/0002-9149(90)90313-p. [DOI] [PubMed] [Google Scholar]
  7. Mueller H. S., Rao A. K., Forman S. A. Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 1987 Sep;10(3):479–490. doi: 10.1016/s0735-1097(87)80188-2. [DOI] [PubMed] [Google Scholar]
  8. Nademanee K., Intarachot V., Josephson M. A., Rieders D., Vaghaiwalla Mody F., Singh B. N. Prognostic significance of silent myocardial ischemia in patients with unstable angina. J Am Coll Cardiol. 1987 Jul;10(1):1–9. doi: 10.1016/s0735-1097(87)80152-3. [DOI] [PubMed] [Google Scholar]
  9. Seifried E., Tanswell P., Ellbrück D., Haerer W., Schmidt A. Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. Thromb Haemost. 1989 Jun 30;61(3):497–501. [PubMed] [Google Scholar]
  10. Simoons M. L., Serruys P. W., van den Brand M., Res J., Verheugt F. W., Krauss X. H., Remme W. J., Bär F., de Zwaan C., van der Laarse A. Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival. J Am Coll Cardiol. 1986 Apr;7(4):717–728. doi: 10.1016/s0735-1097(86)80329-1. [DOI] [PubMed] [Google Scholar]
  11. Smalling R. W., Schumacher R., Morris D., Harder K., Fuentes F., Valentine R. P., Battey L. L., Jr, Merhige M., Pitts D. E., Lieberman H. A. Improved infarct-related arterial patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction: results of a multicenter randomized trial of two dosage regimens. J Am Coll Cardiol. 1990 Apr;15(5):915–921. doi: 10.1016/0735-1097(90)90216-c. [DOI] [PubMed] [Google Scholar]
  12. Tanswell P., Seifried E., Su P. C., Feuerer W., Rijken D. C. Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. Clin Pharmacol Ther. 1989 Aug;46(2):155–162. doi: 10.1038/clpt.1989.120. [DOI] [PubMed] [Google Scholar]
  13. Topol E. J., George B. S., Kereiakes D. J., Stump D. C., Candela R. J., Abbottsmith C. W., Aronson L., Pickel A., Boswick J. M., Lee K. L. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation. 1989 Feb;79(2):281–286. doi: 10.1161/01.cir.79.2.281. [DOI] [PubMed] [Google Scholar]
  14. Verstraete M., Arnold A. E., Brower R. W., Collen D., de Bono D. P., De Zwaan C., Erbel R., Hillis W. S., Lennane R. J., Lubsen J. Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate. Am J Cardiol. 1987 Aug 1;60(4):231–237. doi: 10.1016/0002-9149(87)90219-0. [DOI] [PubMed] [Google Scholar]
  15. Verstraete M., Bernard R., Bory M., Brower R. W., Collen D., de Bono D. P., Erbel R., Huhmann W., Lennane R. J., Lubsen J. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. Lancet. 1985 Apr 13;1(8433):842–847. doi: 10.1016/s0140-6736(85)92208-1. [DOI] [PubMed] [Google Scholar]
  16. Verstraete M., Bleifeld W., Brower R. W., Charbonnier B., Collen D., de Bono D. P., Dunning A. J., Lennane R. J., Lubsen J., Mathey D. G. Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet. 1985 Nov 2;2(8462):965–969. doi: 10.1016/s0140-6736(85)90523-9. [DOI] [PubMed] [Google Scholar]
  17. Verstraete M., van de Werf F., Tranchesi B., Chamone D. F., Pelaggi F. Bolus alteplase. Lancet. 1989 Oct 21;2(8669):989–990. doi: 10.1016/s0140-6736(89)91004-0. [DOI] [PubMed] [Google Scholar]
  18. White H. D., Rivers J. T., Maslowski A. H., Ormiston J. A., Takayama M., Hart H. H., Sharpe D. N., Whitlock R. M., Norris R. M. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N Engl J Med. 1989 Mar 30;320(13):817–821. doi: 10.1056/NEJM198903303201301. [DOI] [PubMed] [Google Scholar]
  19. Wilcox R. G., von der Lippe G., Olsson C. G., Jensen G., Skene A. M., Hampton J. R. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet. 1988 Sep 3;2(8610):525–530. doi: 10.1016/s0140-6736(88)92656-6. [DOI] [PubMed] [Google Scholar]
  20. Williams D. O., Borer J., Braunwald E., Chesebro J. H., Cohen L. S., Dalen J., Dodge H. T., Francis C. K., Knatterud G., Ludbrook P. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial. Circulation. 1986 Feb;73(2):338–346. doi: 10.1161/01.cir.73.2.338. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES